Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.45 |
| ▸ | PDE4A | P27815 | 13/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5703639 | 0.92 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DCASP1 | |
| SCHEMBL8677454 | 0.90 | PDE4D (0.46) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL11830247 | 0.88 | CASP1 (0.54) | CASP1HSD17B10POLB | |
| SCHEMBL27617802 | 0.83 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4DCASP1 | |
| SCHEMBL5498116 | 0.83 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DCASP1 | |
| SCHEMBL5498111 | 0.83 | CASP1 (0.49) | PDE4BPDE4APDE4CPDE4DCASP1 | |
| SCHEMBL8192323 | 0.81 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DPDE5A | |
| SCHEMBL7532617 | 0.80 | PDE4D (0.51) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6815488 | 0.79 | CASP1 (0.54) | PDE4BPDE4APDE4CPDE4DCASP1 | |
| SCHEMBL7384417 | 0.79 | HSD17B10 (0.66) | CASP1HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1524268-B1 | Compounds and method for preparing sustituted 4-phenyl-4-cyanocyclohexanoic acids | SMITHKLINE BEECHAM CORP (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1295869-B1 | Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids | SMITHKLINE BEECHAM CORP (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1524268-A1 | Compounds and method for preparing sustituted 4-phenyl-4-cyanocyclohexanoic acids | SmithKline Beecham Corporation (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1043930-A4 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | SMITHKLINE BEECHAM CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1327627-A1 | Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids | SmithKline Beecham Corporation (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030083507-A1 | Treating chronic bronchial asthma by activating adenylate cyclase and inhibiting phosphodiesterase; principal airway smooth muscle relaxation; suppresses cell degranulation; from an oxaspiro-2.5-octane-2,6-dinitrile analog | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | disclosed |
| EP-1023279-B1 | COMPOUNDS AND METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | SMITHKLINE BEECHAM (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1295869-A2 | Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids | Smithkline Beecham (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6452022-B1 | HEATING ALKALI OR ALKALINE EARTH METAL HALIDE, AND 6-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL))-1-OXASPIRO(2.5)OCTANE-2,6 -DICARBONITRILE IN SOLVENT; ADDING STRONG BASE, REMOVING WATER AND SOLVENT | SMITHKLINE BEECHAM CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020082440-A1 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION | 2002-06-27 | — | — | US | disclosed |
| US-6337408-B1 | HALOGENATED COMPOUNDS WITH BENZENECYCLOHEXANE COMPOUNDS FROM EPOXY COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2002-01-08 | — | — | US | disclosed |
| EP-1043930-A1 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999018793-A1 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083507-A1 | Treating chronic bronchial asthma by activating adenylate cyclase and inhibiting phosphodiesterase; principal airway smooth muscle relaxation; suppresses cell degranulation; from an oxaspiro-2.5-octane-2,6-dinitrile analog | PDE3A, PDE3B, PDE2A | PDE4B 13/4885PDE4A 10/4885PDE4C 23/4885 |
| US-20020082440-A1 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | PCCA, CA6, CA4 | PDE4B 2865/4885PDE4A 2842/4885PDE4C 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.